SECTION 1. IDENTIFICATION

Product name : Abamectin / Fluazuron Formulation

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
          Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Flammable liquids : Category 3
Acute toxicity (Oral) : Category 4
Acute toxicity (Inhalation) : Category 4
Eye irritation : Category 2A
Skin sensitization : Category 1
Reproductive toxicity : Category 1B
Specific target organ toxicity - single exposure : Category 3
Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

GHS label elements
Hazard pictograms : 

Signal Word : Danger
Hazard Statements : H226 Flammable liquid and vapor.
H302 + H332 Harmful if swallowed or if inhaled.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary Statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P202 Do not handle until all safety precautions have been read and understood.
- P210 Keep away from heat/sparks/open flames/hot surfaces. No smoking.
- P233 Keep container tightly closed.
- P241 Use explosion-proof electrical/ventilating/lighting/equipment.
- P242 Use only non-sparking tools.
- P243 Take precautionary measures against static discharge.
- P260 Do not breathe mist or vapors.
- P264 Wash skin thoroughly after handling.
- P270 Do not eat, drink or smoke when using this product.
- P271 Use only outdoors or in a well-ventilated area.
- P280 Wear protective gloves/protective clothing/eye protection/face protection.

**Response:**
- P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
- P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower.
- P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.
- P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P308 + P313 IF exposed or concerned: Get medical advice/attention.
- P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
- P337 + P313 If eye irritation persists: Get medical advice/attention.
- P363 Wash contaminated clothing before reuse.

**Storage:**
- P403 + P235 Store in a well-ventilated place. Keep cool.
- P405 Store locked up.

**Disposal:**
- P501 Dispose of contents/container to an approved waste disposal plant.
Other hazards
Vapors may form explosive mixture with air.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemical name</td>
</tr>
<tr>
<td></td>
<td>Propan-2-ol</td>
</tr>
<tr>
<td></td>
<td>N-Methyl-2-pyrrolidone</td>
</tr>
<tr>
<td></td>
<td>Fluazuron</td>
</tr>
<tr>
<td></td>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
</tr>
<tr>
<td></td>
<td>7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed or if inhaled. May cause an allergic skin reaction. Causes serious eye irritation. May cause respiratory irritation. May cause drowsiness or dizziness. May damage the unborn child. Suspected of damaging fertility. Causes damage to organs through prolonged or repeated exposure if swallowed. May cause damage to organs through prolonged or repeated exposure.
**Protection of first-aiders:** First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Notes to physician:** Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

**Suitable extinguishing media:**
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media:** High volume water jet

**Specific hazards during fire fighting:**
- Do not use a solid water stream as it may scatter and spread fire.
- Flash back possible over considerable distance.
- Vapors may form explosive mixtures with air.
- Exposure to combustion products may be a hazard to health.

**Hazardous combustion products:**
- Carbon oxides
- Nitrogen oxides (NOx)
- Chlorine compounds
- Fluorine compounds

**Specific extinguishing methods:**
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for fire-fighters:**
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures:**
- Remove all sources of ignition.
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

**Environmental precautions:**
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g., by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up:**
- Non-sparking tools should be used.
- Soak up with inert absorbent material.
- Suppress (knock down) gases/vapors/mists with a water spray jet.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate
Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation. If advised by assessment of the local exposure potential, use only in an area equipped with explosion-proof exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe vapors or spray mist. Do not swallow. Do not get in eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Non-sparking tools should be used. Keep container tightly closed. Already sensitized individuals should consult their physician regarding working with respiratory irritants or sensitizers. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.


Materials to avoid: Do not store with the following product types: Strong oxidizing agents Organic peroxides Flammable solids Pyrophoric liquids Pyrophoric solids Self-heating substances and mixtures Substances and mixtures which in contact with water emit flammable gases Explosives Gases
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propan-2-ol</td>
<td>67-63-0</td>
<td>TWA</td>
<td>200 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL</td>
<td>400 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA 980 mg/m³</td>
<td>400 ppm</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ST 1,225 mg/m³</td>
<td>500 ppm</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>400 ppm 980 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>TWA</td>
<td>10 ppm</td>
<td>US WEEL</td>
</tr>
<tr>
<td>Fluazuron</td>
<td>86811-58-7</td>
<td>TWA</td>
<td>60 µg/m³ (OEB 3) Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit 600 µg/100cm²</td>
<td>Internal</td>
<td></td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 µg/m³ (OEB 3) Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit 300 µg/100 cm²</td>
<td>Internal</td>
<td></td>
</tr>
</tbody>
</table>

Biological occupational exposure limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters</th>
<th>Biological specimen</th>
<th>Sampling time</th>
<th>Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>5-Hydroxy-N-methyl-2-pyrrolidone</td>
<td>Urine</td>
<td>End of shift (As soon as possible after exposure ceases)</td>
<td>100 mg/l</td>
<td>ACGIH BEI</td>
</tr>
<tr>
<td>Propan-2-ol</td>
<td>67-63-0</td>
<td>Acetone</td>
<td>Urine</td>
<td>End of shift at end of work-week</td>
<td>40 mg/l</td>
<td>ACGIH BEI</td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: General and local exhaust ventilation is recommended to
Maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving. Take note that the product is flammable, which may impact the selection of hand protection.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: liquid
Color: No data available
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
### Initial boiling point and boiling range
- No data available

### Flash point
- 82 °F / 28 °C

### Evaporation rate
- No data available

### Flammability (solid, gas)
- Not applicable

### Flammability (liquids)
- Not applicable

### Upper explosion limit / Upper flammability limit
- No data available

### Lower explosion limit / Lower flammability limit
- No data available

### Vapor pressure
- No data available

### Relative vapor density
- No data available

### Relative density
- No data available

### Density
- No data available

### Solubility(ies)
- Water solubility
  - No data available

### Partition coefficient: n-octanol/water
- Not applicable

### Autoignition temperature
- No data available

### Decomposition temperature
- No data available

### Viscosity
- Viscosity, kinematic
  - No data available

### Explosive properties
- Not explosive

### Oxidizing properties
- The substance or mixture is not classified as oxidizing.

### Molecular weight
- No data available

### Particle size
- Not applicable

### SECTION 10. STABILITY AND REACTIVITY

#### Reactivity
- Not classified as a reactivity hazard.

#### Chemical stability
- Stable under normal conditions.
- Flammable liquid and vapor.
- Vapors may form explosive mixture with air.
- Can react with strong oxidizing agents.
## Conditions to avoid
- Heat, flames and sparks.
- Oxidizing agents

## Incompatible materials
- Oxidizing agents

## Hazardous decomposition products
- No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

- **Inhalation**
- **Skin contact**
- **Ingestion**
- **Eye contact**

#### Acute toxicity
- Harmful if swallowed or if inhaled.

#### Product

- **Acute oral toxicity**
  - Acute toxicity estimate: 1,824 mg/kg
  - Method: Calculation method

- **Acute inhalation toxicity**
  - Acute toxicity estimate: 2.06 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Method: Calculation method

- **Acute dermal toxicity**
  - Acute toxicity estimate: > 5,000 mg/kg
  - Method: Calculation method

#### Components

- **Propan-2-ol**
  - **Acute oral toxicity**
    - LD50 (Rat): > 5,000 mg/kg
  - **Acute inhalation toxicity**
    - LC50 (Rat): > 25 mg/l
    - Exposure time: 6 h
    - Test atmosphere: vapor
  - **Acute dermal toxicity**
    - LD50 (Rabbit): > 5,000 mg/kg

- **N-Methyl-2-pyrrolidone**
  - **Acute oral toxicity**
    - LD50 (Rat): 4,150 mg/kg
  - **Acute inhalation toxicity**
    - LC50 (Rat): > 5.1 mg/l
    - Exposure time: 4 h
    - Test atmosphere: dust/mist
    - Method: OECD Test Guideline 403
    - Assessment: The substance or mixture has no acute inhalation toxicity
  - **Acute dermal toxicity**
    - LD50 (Rat): > 5,000 mg/kg

- **Fluazuron**
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity: LC50 (Rat): > 6.0 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402

Abamectin (combination of avermectin B1a and avermectin B1b):
Acute oral toxicity: LD50 (Rat): 24 mg/kg  
LD50 (Mouse): 10 mg/kg  
LDLo (Monkey): 24 mg/kg  
Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0.023 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg  
LD50 (Rabbit): 2,000 mg/kg

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:
Acute oral toxicity: LD50 (Rat, male): 2,959 - 5,000 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity: LC50 (Rat): >= 5.19 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 436  
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

Propan-2-ol:
Species: Rabbit  
Result: No skin irritation

N-Methyl-2-pyrrolidone:
<table>
<thead>
<tr>
<th>Components</th>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluazuron</strong></td>
<td>Rabbit</td>
<td>No skin irritation</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 404</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>No skin irritation</td>
</tr>
<tr>
<td><strong>Abamectin (combination of avermectin B1a and avermectin B1b)</strong>:</td>
<td>Rabbit</td>
<td>No skin irritation</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>No skin irritation</td>
</tr>
<tr>
<td><strong>7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate</strong>:</td>
<td>Rabbit</td>
<td>No skin irritation</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>No skin irritation</td>
</tr>
<tr>
<td><strong>Serious eye damage/eye irritation</strong></td>
<td></td>
<td>Causes serious eye irritation.</td>
</tr>
<tr>
<td><strong>Components</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Propan-2-ol</strong></td>
<td>Rabbit</td>
<td>Irritation to eyes, reversing within 21 days</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>Irritation to eyes, reversing within 21 days</td>
</tr>
<tr>
<td><strong>N-Methyl-2-pyrrolidone</strong></td>
<td></td>
<td>Based on harmonised classification in EU regulation 1272/2008, Annex VI</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>Based on harmonised classification in EU regulation 1272/2008, Annex VI</td>
</tr>
<tr>
<td>Remarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fluazuron</strong></td>
<td>Rabbit</td>
<td>Mild eye irritation</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>Mild eye irritation</td>
</tr>
<tr>
<td><strong>Abamectin (combination of avermectin B1a and avermectin B1b)</strong>:</td>
<td>Rabbit</td>
<td>Mild eye irritation</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>Mild eye irritation</td>
</tr>
<tr>
<td><strong>7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate</strong>:</td>
<td>Rabbit</td>
<td>No eye irritation</td>
</tr>
<tr>
<td>Species:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method:</td>
<td>OECD Test Guideline 405</td>
<td></td>
</tr>
<tr>
<td>Result:</td>
<td>Rabit</td>
<td>No eye irritation</td>
</tr>
<tr>
<td><strong>Respiratory or skin sensitization</strong></td>
<td></td>
<td>May cause an allergic skin reaction.</td>
</tr>
</tbody>
</table>
Respiratory sensitization
Not classified based on available information.

Components:

Propan-2-ol:
Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

N-Methyl-2-pyrrolidone:
Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Method: OECD Test Guideline 429
Result: negative
Remarks: Based on data from similar materials

Fluazuron:
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
Test Type: Maximization Test
Routes of exposure: Skin contact
Result: Not a skin sensitizer.

7-Oxabicyclo[4.1.0]heptan-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: positive
Assessment: Probability or evidence of skin sensitization in humans

Germ cell mutagenicity
Not classified based on available information.

Components:

Propan-2-ol:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
SAFETY DATA SHEET

Abamectin / Fluazuron Formulation

Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

N-Methyl-2-pyrrolidone:
Genotoxicity in vitro :
Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Genotoxicity in vivo :
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative

Fluazuron:
Genotoxicity in vitro :
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: DNA Repair
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo :
Test Type: Cytogenetic assay
Species: Hamster
Result: equivocal

Abamectin (combination of avermectin B1a and avermectin B1b):
Genotoxicity in vitro :
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo :
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:
SAFETY DATA SHEET

Abamectin / Fluazuron Formulation

Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
- Result: positive

Genotoxicity in vivo:
- Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 486
  - Result: negative
- Test Type: Micronucleus test
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Result: negative

Germ cell mutagenicity - Assessment:
- Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity:
- Not classified based on available information.

Components:

Propan-2-ol:
- Species: Rat
- Application Route: Inhalation (vapor)
- Exposure time: 104 weeks
- Method: OECD Test Guideline 451
- Result: negative

N-Methyl-2-pyrrolidone:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 2 Years
- Result: negative

Fluazuron:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 2 Years
- Method: OECD Test Guideline 453
- Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
- Species: Rat
- Application Route: Oral
- Exposure time: 105 weeks
## Abamectin / Fluazuron Formulation

<table>
<thead>
<tr>
<th>Result</th>
<th>negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>93 weeks</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

**IARC**
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

**NTP**
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.

**Components:**

#### Propan-2-ol:

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Two-generation reproduction toxicity study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

#### N-Methyl-2-pyrrolidone:

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Two-generation reproduction toxicity study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
<td></td>
</tr>
<tr>
<td>Method: OECD Test Guideline 416</td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
<td></td>
</tr>
<tr>
<td>Method: OECD Test Guideline 414</td>
<td></td>
</tr>
<tr>
<td>Result: positive</td>
<td></td>
</tr>
</tbody>
</table>

| Test Type: Fertility/early embryonic development |
| Species: Rat |
| Application Route: inhalation (vapor) |
| Result: positive |

<table>
<thead>
<tr>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Result: positive</td>
</tr>
</tbody>
</table>
Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

Fluazuron:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
Effects on fertility: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects., Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects.

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:
Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

STOT-single exposure
May cause respiratory irritation.
May cause drowsiness or dizziness.

Components:

Propan-2-ol:
Assessment: May cause drowsiness or dizziness.

N-Methyl-2-pyrrolidone:
Assessment: May cause respiratory irritation.
Remarks: Based on harmonised classification in EU regulation 1272/2008, Annex VI

STOT-repeated exposure
Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Routes of exposure: Ingestion
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Propan-2-ol:
Species: Rat
NOAEL: 12.5 mg/l
Application Route: inhalation (vapor)
Exposure time: 104 Weeks
### N-Methyl-2-pyrrolidone:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat, male</td>
</tr>
<tr>
<td>NOAEL</td>
<td>169 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>433 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 408</td>
</tr>
</tbody>
</table>

### Fluazuron:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>LOAEL</td>
<td>240 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Thyroid, Pituitary gland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>NOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>100 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Dog</td>
</tr>
<tr>
<td>NOAEL</td>
<td>7.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>110 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>52 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
</tbody>
</table>

### Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>NOAEL</td>
<td>1.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>NOAEL</td>
<td>4.0 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Dog</td>
</tr>
<tr>
<td>NOAEL</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, weight loss</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Monkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, weight loss</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Monkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, weight loss</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Ingestion:
Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
Propan-2-ol:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 9,640 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 24 h

Toxicity to microorganisms: EC50 (Pseudomonas putida): > 1,050 mg/l
Exposure time: 16 h

N-Methyl-2-pyrrolidone:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: DIN 38412

Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
Exposure time: 72 h
EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 12.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms: EC50: > 600 mg/l
Exposure time: 30 min
Method: ISO 8192
Fluazuron:
Toxicity to fish: LC50 (Cyprinus carpio (Carp)): > 9.1 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia sp. (Water flea)): 0.0006 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: NOEC (Raphidocelis subcapitata (freshwater green alga)): 27.9 mg/l
Exposure time: 72 h

Abamectin (combination of avermectin B1a and avermectin B1b):
Toxicity to fish:
- LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
  Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
  Exposure time: 96 h
- LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
  Exposure time: 96 h
- LC50 (Cyprinus carpio (Carp)): 42 µg/l
  Exposure time: 96 h
- LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
  Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Americanysis): 0.022 µg/l
  Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): 0.34 µg/l
  Exposure time: 48 h

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  Exposure time: 72 h

Toxicity to fish (Chronic toxicity):
- NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
  Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 0.03 µg/l
  Exposure time: 21 d
- NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
  Exposure time: 28 d

Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:
Toxicity to fish:
- LC50 (Oncorhynchus mykiss (rainbow trout)): 24 mg/l
  Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): 40 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:
ErC50 (Selenastrum capricornutum (green algae)): > 110 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Selenastrum capricornutum (green algae)): 30 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms:
EC10 (Natural microorganism): 409 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Propan-2-ol:
Biodegradability: Result: rapidly degradable
BOD/COD: BOD: 1.19 (BOD5)COD: 2.23BOD/COD: 53 %

N-Methyl-2-pyrrolidone:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Abamectin (combination of avermectin B1a and avermectin B1b):
Stability in water: Hydrolysis: 50 % (< 12 h)

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:
Biodegradability: Biodegradation: 71 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Stability in water: Degradation half life (DT50): 2 d

Bioaccumulative potential

Components:

Propan-2-ol:
Partition coefficient: n-octanol/water: log Pow: 0.05

N-Methyl-2-pyrrolidone:
**Abamectin / Fluazuron Formulation**

**Partition coefficient**: n-octanol/water

**Fluazuron**:  
- log Pow: -0.46

**Abamectin (combination of avermectin B1a and avermectin B1b)**:
- log Pow: 5.1
- Bioaccumulation: Bioconcentration factor (BCF): 52
- log Pow: 4

**7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate**:  
- log Pow: 1.34

**Mobility in soil**

**Components**:

**Abamectin (combination of avermectin B1a and avermectin B1b)**:
- Distribution among environmental compartments: log Koc: > 3.6

**Other adverse effects**
- No data available

**SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods**

- **Waste from residues**: Dispose of in accordance with local regulations.
- **Contaminated packaging**: Empty containers should be taken to an approved waste handling site for recycling or disposal. Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or death. If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**
- **UN number**: UN 1993
- **Proper shipping name**: FLAMMABLE LIQUID, N.O.S.
  - (Propan-2-ol)
- **Class**: 3
- **Packing group**: III
- **Labels**: 3

**IATA-DGR**
- **UN/ID No.**: UN 1993
- **Proper shipping name**: Flammable liquid, n.o.s.
SAFETY DATA SHEET

Abamectin / Fluazuron Formulation

Class: 3
Packing group: III
Labels: Flammable Liquids
Packing instruction (cargo aircraft): 366
Packing instruction (passenger aircraft): 355

IMDG-Code
UN number: UN 1993
Proper shipping name: FLAMMABLE LIQUID, N.O.S. (Propan-2-ol, Fluazuron, Abamectin (combination of avermectin B1a and avermectin B1b))

Class: 3
Packing group: III
Labels: 3
EmS Code: F-E, S-E
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
UN/ID/NA number: UN 1993
Proper shipping name: Flammable liquids, n.o.s. (Propan-2-ol)
Class: 3
Packing group: III
Labels: FLAMMABLE LIQUID
ERG Code: 128
Marine pollutant: yes(Fluazuron, Abamectin (combination of avermectin B1a and avermectin B1b))

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know
CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards: Flammable (gases, aerosols, liquids, or solids)
Acute toxicity (any route of exposure)
Serious eye damage or eye irritation
Respiratory or skin sensitization
Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : The following components are subject to reporting levels established by SARA Title III, Section 313:

- Propan-2-ol 67-63-0 >= 30 - < 50 %
- N-Methyl-2-pyrrolidone 872-50-4 >= 30 - < 50 %
- Abamectin (combination of avermectin B1a and avermectin B1b) 71751-41-2 >= 1 - < 5 %

US State Regulations

Pennsylvania Right To Know

- Propan-2-ol 67-63-0
- N-Methyl-2-pyrrolidone 872-50-4
- Poly[oxy(methyl-1,2-ethanediyl)], α-(1-oxotetradecyl)-ω-(phenylmethoxy) 642443-86-5

California Prop. 65
WARNING: This product can expose you to chemicals including N-Methyl-2-pyrrolidone, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous Substances

- Propan-2-ol 67-63-0

California Permissible Exposure Limits for Chemical Contaminants

- Propan-2-ol 67-63-0
- N-Methyl-2-pyrrolidone 872-50-4

The ingredients of this product are reported in the following inventories:

- AICS : not determined
- DSL : not determined
- IECSC : not determined
SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

<table>
<thead>
<tr>
<th>Health</th>
<th>Flammability</th>
<th>Special hazard</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>* 3</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH: USA. ACGIH Threshold Limit Values (TLV)
ACGIH BEI: ACGIH - Biological Exposure Indices (BEI)
NIOSH REL: USA. NIOSH Recommended Exposure Limits
OSHA Z-1: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
US WEEL: USA. Workplace Environmental Exposure Levels (WEEL)
ACGIH / TWA: 8-hour, time-weighted average
ACGIH / STEL: Short-term exposure limit
NIOSH REL / TWA: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / ST: STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
OSHA Z-1 / TWA: 8-hour time weighted average
US WEEL / TWA: 8-hr TWA

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LDS0 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-
SAFETY DATA SHEET

Abamectin / Fluazuron Formulation

Version: 7.1  Revision Date: 09/13/2019  SDS Number: 800410-00013  Date of last issue: 04/24/2019
Date of first issue: 07/12/2016

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8